Panel-based pharmacogenetic genotyping for Prescription Drug Use
This trial will test if a preemptive clinical pharmacogenetic test can improve patient outcomes by better personalized drug therapy. Data from this trial will also help understand when and how to implement this innovative healthcare technology into clinical care.
- Prescription Drug Use
- Pharmacogenetic Testing
1 Primary · 0 Secondary · Reporting Duration: 12-14 months
1 Treatment Group
Immediate panel-based pharmacogenetic genotyping
1 of 1
492 Total Participants · 1 Treatment Group
Primary Treatment: Panel-based pharmacogenetic genotyping · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any available opportunities for individuals to join this trial?
"Clinicaltrials.gov reports that this particular medical trial is still recruiting volunteers. This study was initially posted on the 1st of August 2022 and saw its last update on the 5th of August 2022." - Anonymous Online Contributor
How many individuals are eligible for this medical experiment?
"Indeed, research on clinicaltrials.gov affirms that this experiment is actively recruiting participants. The study was first uploaded to the website on August 1st 2022 and has been recently revised for accuracy as of August 5th 2022. As such, 492 individuals across a single location are needed in order to complete it successfully." - Anonymous Online Contributor